Barsouk A, Elghawy O, Heidlauf A, Yu C, et al. Real-world outcomes of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC)treated with osimertinib (osi) vs. Afatinib or erlotinib. Lung Cancer 2024;195:107926.
PMID: 39137595